• Contact us: 01476 247 007
    GCP Inspections: Expectations and the dos and don’ts for hostingGCP Inspections: Expectations and the dos and don’ts for hostingGCP Inspections: Expectations and the dos and don’ts for hostingGCP Inspections: Expectations and the dos and don’ts for hosting
    • How can we help
      • Pharmacovigilance
        • National contact person for pharmacovigilance – post Brexit
        • Pharmacovigilance Standard Operating Procedure Audits
        • Post Marketing Pharmacovigilance Support
        • Clinical Trial Pharmacovigilance Support
        • EU QPPV Provision
        • Quality & Compliance
        • Risk Assessment and Management
        • Signal Detection and Management
      • Medical Writing
      • Patient Information
      • Regulatory
      • Market Authorisation Holding
    • Brexit
    • Our Partners
      • Marti Farm
      • Affiliates
      • Medilink
      • External Team
    • News
    • Get in touch
    It's business as usual at PDS during the coronavirus / COVID-19 crisis
    Coronavirus / COVID-19 – business as usual at PDS
    13th March 2020
    Business as usual at Pure Drug Safety despite the continuing coronavirus pandemic
    Business as usual at Pure Drug Safety
    15th May 2020

    GCP Inspections: Expectations and the dos and don’ts for hosting

    19th March 2020
    GCP Inspections: Expectations and the dos and don’ts for hosting

    GCP Inspections: Expectations and the dos and don’ts for hostingGood Clinical Practice (GCP) inspections and how they are conducted has evolved massively over the years and has had to, due to the increased complexity of trials, organisations, implementation of electronic clinical trial systems and the development of technology.

    No longer are clinical trial teams based in one office with a paper trial master file (TMF).

    GCP inspections can be challenging for all involved and issues have often been encountered during the inspection conduct to do with TMF access and navigation, document request provision and sometimes simply finding the right person to answer a particular question. This is why the MHRA Inspectorate has released updated information on what should you expect from a routine statutory GCP systems inspection, and what can you do to ensure the inspection goes smoothly.

    Please click HERE to read the article in full.

     

     

    Share

    Related posts

    21st July 2021

    The clock is ticking! Have you appointed your National Contact Person for Pharmacovigilance yet?


    Read more
    Advice for Management of Clinical trials in relation to Coronavirus
    13th March 2020

    Advice for Management of Clinical trials in relation to Coronavirus


    Read more
    NICE agrees to look again at Novartis’ Aimovig for migraine prevention
    17th February 2020

    Good news for severe migraine suffers everywhere as NICE agrees to look again at Novartis’ Aimovig for migraine prevention


    Read more

    PLEASE NOTE OUR NEW PHONE NUMBER AS OF 1st JUNE 2021
    Call our team +44(0) 1476 247 007
    email info@puredrugsafety.com



    Sign up for our newsletter

    Pure Drug Safety Ltd

    Pure Drug Safety Ltd · 1 year ago
    @PureDrugSafety



    Many clients have already put their NCPP in place with us here at PDS and are ready for January 2022.

    Read more 👉 https://t.co/6mnM9Dzoma

    #NationalContactPerson #KnowledgeablePerson #ExperiencedQppv https://t.co/rS2W4PZbDv

    View on Twitter


    0

    0

    © 2019 - 2023 Pure Drug Safety.
    As of 1st June 2021 NEW OFFICE & REGISTERED ADDRESS: BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF, UK
    Pure Drug Safety Limited is a company registered in England and Wales. Registered Company Number 7702236. VAT Registered Number 117 966 288
    For our GDPR and Privacy Policy click here
    Designed by Gather Creative | Content managed by Tailored Marketing Solutions | Built + Hosted by GIGER MEDIA